ADVAC, LLC

Biotech · Private

virus-like particle (VLP) vaccines containing M2e and neuraminidase antigens for cross-protective influenza immunization

Grants
$497K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · New RSV Vaccines with Improved Safety and Efficacy$225,000
Federal grantDepartment of Health and Human Services · Phase I · Multi NA-based influenza vaccines$272,223
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1348NEURO10-9 PHARMA INC——
1349OXT THERAPEUTICS, INC.——
1350COVENANT THERAPEUTICS, LLC——
1351ADVAC, LLC——
1352CALEO BIOTECHNOLOGIES, INC.——
1353SOLVEXA, LLC——
1354AltruBio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.